Extended-release Buprenorphine

DRUG2 trials

Sponsors

Indivior Inc., Brigham and Women's Hospital

Conditions

Moderate to Severe Opioid-use DisorderOpioid Use Disorder

Phase 2

Extended-release Buprenorphine as a Novel Low-dose Induction Strategy

Active, not recruitingNCT06441604

Brigham and Women's HospitalOpioid Use Disorder

Start: 2025-10-27End: 2027-01-31Updated: 2026-07-09

Phase 4

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

CompletedNCT04995029

Indivior Inc.Moderate to Severe Opioid-use Disorder

Start: 2021-10-26End: 2024-06-26Updated: 2026-02-06